Full Press Release Details
National Stock Exchange of India Ltd. (Scrip
BSE Limited (Scrip Code: 500124)
Further to our intimation dated July 7,
2022, on the inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing
facility (FTO 11) in Srikakulam, Andhra Pradesh, we wish to inform you that the Company has received the Establishment Inspection
Report (EIR). The Agency has concluded that the inspection is "closed" under 21 C.F.R.20.64(d)(3).
This is for your information.
| Yours faithfully, | |
| For Dr. Reddy's Laboratories Limited | |
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary & Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock